Navigation Links
ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
Date:1/18/2008

of a range of vascular diseases. The Company has several programs in Phase II clinical development including microplasmin, which is being evaluated as a treatment for vitreoretinal disorders and as a thrombolytic agent for vascular occlusive diseases, including acute stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), scheduled to enter Phase II clinical development in 2008, and TB-403 (Anti-PlGF), which has received approval to begin Phase I clinical trials for the treatment of cancer. ThromboGenics has built strong links with the University of Leuven and has exclusive rights to certain therapeutics developed at the University. ThromboGenics is headquartered in Leuven, Belgium and has subsidiaries in Dublin, Ireland and New York, U.S. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

About BioInvent

BioInvent International AB, listed on The Nordic Exchange (OMXS:BINV), is a research-based pharmaceutical company that focuses on developing antibody drugs. The Company is currently running innovative drug projects within the areas of thrombosis, cancer, atherosclerosis and ophthalmic diseases. In January 2007 the Company announced a major strategic alliance with American-based Genentech, Inc. in the cardiovascular field. These projects are based on a competitive and in substance patented technology platform. The scope and strength of this platform is also utilised by partners, such as ALK-Abello, ImmunoGen, OrbusNeich, Sanofi-Aventis, UCB and XOMA.

The Company, which currently has 96 employees, is located at Ideon in Lund.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements a
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
2. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
3. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
4. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
5. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
6. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. Agennix Receives Special Protocol Assessment Approval from FDA for the Pivotal Trial of Talactoferrin Alfa in First-Line Non-Small Cell Lung Cancer
9. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
10. Genta Receives Notice of Non-Compliance With NASDAQ Rule
11. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... When a leading manufacturer of ... to design an industrial oven that ... being produced using a 3D-printing process, Gruenberg engineers ... gantry, heat-saving windows, and internal actuators and sensors ... pills to exact specifications. , To ensure the ...
(Date:5/29/2015)... Research and Markets ( http://www.researchandmarkets.com/research/7bf7ff/cytogenetics ) ... report "Cytogenetics - Technologies, Markets and Companies" ... deals with cytogenetics in a broader sense rather ... chromosome structure and identify abnormalities related to disease. ... also referred to as molecular cytogenetics. The scope ...
(Date:5/29/2015)... Seoul Semiconductor (CEO: Chung-hoon Lee, http://www.seoulsemicon.com ), ... announced that it will increase the global automotive ... and high reliable LED product line-up for the ... developed efficient and reliable LED packages for the ... headlamps to global auto makers. Seoul Semiconductor’s 14 ...
(Date:5/28/2015)... DUBLIN , May 28, 2015 /PRNewswire/ ... http://www.researchandmarkets.com/research/7k46bt/therapeutic_drug ) has announced the addition of ... Monitoring - Technologies, Markets, and Companies" ... http://photos.prnewswire.com/prnh/20130307/600769) , This report deals ... specialty, aimed at improving patient care by ...
Breaking Biology Technology:New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 2Global Cytogenetics Market Report 2015-2024 - Technologies, Markets and Companies 3Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Global Therapeutic Drug Monitoring Market 2015-2024 2
... Recruitment of 66 CLL,Patients Respectively to Both Study ... COPENHAGEN, Denmark, November 28 Genmab A/S,(OMX: GEN) ... completed,in a pivotal study of ofatumumab (HuMax-CD20(R)) for ... cohort comprises 66,patients who are refractory to both ...
... at the National Institute of Standards and Technology ... eventually leads to cracks and breakdown in bulk ... long has been thought not to exist. Their ... design of new silicon-based micro-electromechanical system (MEMS) devices ...
... 27 Nastech,Pharmaceutical Company Inc. (Nasdaq: NSTK ) ... Markets Focus on Healthcare Conference on,Wednesday, December 5, 2007 ... in New York City., To access the live ... website at http://www.nastech.com approximately 15 minutes prior,to ...
Cached Biology Technology:Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study 2Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study 3Job-related stress: NIST demonstrates fatigue effects in silicon 2
(Date:5/18/2015)... , May 18, 2015 Fingerprint Cards ... FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from one if its ... until and including Q3 2015 and the sensors will be ... Communicated order values for 2015 hereby amount to 740 MSEK ... 2015 of 140 MSEK and a number of smaller orders ...
(Date:5/11/2015)... May 11, 2015  Synaptics Incorporated (NASDAQ: ... solutions, today announced the appointment of Wajid ... Financial Officer, reporting to Rick Bergman , ... Chief Financial Officer, Kathleen Bayless , who ... Mr. Ali brings extensive financial management expertise ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an order for ... World Peace Industrial Group (WPI), part of WPG Holdings. WPI ... . Deliveries are planned to take place during Q3 2015 ... China . The order value of 235 ... 1 000 MSEK for 2015.   Jörgen Lantto, acting ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... 2011) As the American military rushes to ... ranges, the Department of Defense is giving $4 million ... Colorado School of Medicine to develop revolutionary ways to ... The Altitude Research Center, the only civilian institution ...
... today released new tiger population numbers for the first time ... that has half of the world,s remaining wild tigers. ... up from 1,411 during the last count in 2007. However, ... count, the Sundarbans, that contained 70 tigers. This area was ...
... 28, 2011)Deep vein thrombosis, or DVT: it,s more than ... ride. The Society of Interventional Radiology wants individuals to ... which can lead to post-thrombotic syndrome, pulmonary embolism, permanent ... "Individuals and their doctors need to be aware that ...
Cached Biology News:Altitude Research Center wins major Pentagon grants 2Altitude Research Center wins major Pentagon grants 3India releases tiger numbers as experts convene 2Interventional radiologists take lead on reducing disability from dangerous blood clots 2Interventional radiologists take lead on reducing disability from dangerous blood clots 3Interventional radiologists take lead on reducing disability from dangerous blood clots 4